Tirzepatide combination therapy in psoriasis patients delivered enhanced skin clearance, substantial weight loss, and reduced psoriatic arthritis risk — outcomes that go beyond what conventional biologics targeting IL-17 or IL-23 alone typically achieve. In hidradenitis suppurativa, GLP-1 receptor agonists correlated with improved cardiometabolic markers and fewer systemic complications, though direct anti-inflammatory effects on skin tissue remain mechanistically secondary to their systemic metabolic actions.
This framing matters enormously for clinical practice. Psoriasis and hidradenitis suppurativa patients carry dramatically elevated cardiovascular mortality risk — psoriasis alone confers roughly 25–30% higher major cardiovascular event rates in moderate-to-severe disease. Current standard-of-care immunobiologics address cutaneous inflammation brilliantly but leave metabolic comorbidities largely untouched. GLP-1 receptor agonists fill precisely that gap, potentially offering a 'two-for-one' benefit profile no single existing dermatologic therapy provides.
That said, this is a narrative review synthesizing heterogeneous evidence — clinical trials, observational data, and real-world analyses — not a controlled meta-analysis. Effect sizes and causality remain difficult to isolate, particularly for hidradenitis suppurativa where data density is thin. The paradigm proposed here is intellectually compelling but premature for clinical guidelines. Still, for the substantial cohort of inflammatory skin disease patients who are simultaneously obese, insulin-resistant, or cardiovascularly compromised, GLP-1 receptor agonists warrant serious consideration as adjunct therapy today, not years from now.